Log in

NASDAQ:FTSV - Forty Seven Stock Price, Forecast & News

$95.43
-0.01 (-0.01 %)
(As of 04/3/2020 06:00 AM ET)
Today's Range
$95.41
Now: $95.43
$95.44
50-Day Range
$42.31
MA: $76.56
$95.44
52-Week Range
$5.53
Now: $95.43
$95.44
Volume553,969 shs
Average Volume1.63 million shs
Market Capitalization$4.60 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.38
Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.
Read More
Forty Seven logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FTSV
CUSIPN/A
CIKN/A
Phone650-352-4150

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.68 million
Book Value$7.52 per share

Profitability

Net Income$-87,620,000.00

Miscellaneous

Employees57
Market Cap$4.60 billion
Next Earnings Date5/11/2020 (Estimated)
OptionableNot Optionable

Receive FTSV News and Ratings via Email

Sign-up to receive the latest news and ratings for FTSV and its competitors with MarketBeat's FREE daily newsletter.


Forty Seven (NASDAQ:FTSV) Frequently Asked Questions

How has Forty Seven's stock been impacted by COVID-19 (Coronavirus)?

Forty Seven's stock was trading at $94.66 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, FTSV stock has increased by 0.8% and is now trading at $95.43. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Forty Seven?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Forty Seven in the last year. There are currently 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Forty Seven.

When is Forty Seven's next earnings date?

Forty Seven is scheduled to release its next quarterly earnings announcement on Monday, May 11th 2020. View our earnings forecast for Forty Seven.

How were Forty Seven's earnings last quarter?

Forty Seven Inc (NASDAQ:FTSV) issued its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.38) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.38). The business had revenue of $15.68 million for the quarter, compared to the consensus estimate of $15.80 million. View Forty Seven's earnings history.

What price target have analysts set for FTSV?

11 analysts have issued 12 month price objectives for Forty Seven's stock. Their forecasts range from $18.00 to $95.50. On average, they anticipate Forty Seven's stock price to reach $65.95 in the next twelve months. This suggests that the stock has a possible downside of 30.9%. View analysts' price targets for Forty Seven.

What are Wall Street analysts saying about Forty Seven stock?

Here are some recent quotes from research analysts about Forty Seven stock:
  • 1. According to Zacks Investment Research, "Forty Seven, Inc. is a clinical-stage immuno-oncology company. It focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. The company's product candidate consists of 5F9, is an IgG4 monoclonal antibody against CD47 which is designed to interfere with recognition of CD47 by the SIRP? receptor on macrophages. Forty Seven, Inc. is based in CA, United States. " (3/27/2020)
  • 2. Mizuho analysts commented, "We initiate coverage of FTSV with a Buy rating and $18 PT. We like the speed- to-market program for 5F9 (pivotal readout by 4Q20). We also like the pursuit of a novel mechanism in immuno-oncology, innate immunity via CD47. FTSV has cash into 2021 and readouts that should serve as valuation inflection points." (9/11/2019)

Has Forty Seven been receiving favorable news coverage?

News stories about FTSV stock have been trending very negative on Friday, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Forty Seven earned a news impact score of -3.3 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutForty Seven.

Are investors shorting Forty Seven?

Forty Seven saw a drop in short interest in the month of March. As of March 13th, there was short interest totaling 940,300 shares, a drop of 54.6% from the February 27th total of 2,070,000 shares. Based on an average trading volume of 5,500,500 shares, the days-to-cover ratio is currently 0.2 days. Approximately 3.0% of the company's stock are sold short. View Forty Seven's Current Options Chain.

Who are some of Forty Seven's key competitors?

What other stocks do shareholders of Forty Seven own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Forty Seven investors own include Sorrento Therapeutics (SRNE), Energy Transfer LP Unit (ET), TG Therapeutics (TGTX), Amarin (AMRN), NVIDIA (NVDA), GlycoMimetics (GLYC), Trillium Therapeutics (TRIL), AT&T (T), NovaBay Pharmaceuticals (NBY) and ACADIA Pharmaceuticals (ACAD).

Who are Forty Seven's key executives?

Forty Seven's management team includes the following people:
  • Dr. Mark A. McCamish, Pres, CEO & Director (Age 66)
  • Dr. Craig S. Gibbs, Chief Bus. Officer (Age 56)
  • Dr. Chris H. Takimoto M.D., Ph.D., Chief Medical Officer (Age 60)
  • Mr. Mark Chao, Founder & VP of Clinical Devel.
  • Mr. Jens-Peter Volkmer, Founder and VP of Research & Early Devel.

When did Forty Seven IPO?

(FTSV) raised $100 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity, BTIG and Oppenheimer were co-managers.

What is Forty Seven's stock symbol?

Forty Seven trades on the NASDAQ under the ticker symbol "FTSV."

How do I buy shares of Forty Seven?

Shares of FTSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Forty Seven's stock price today?

One share of FTSV stock can currently be purchased for approximately $95.43.

How big of a company is Forty Seven?

Forty Seven has a market capitalization of $4.60 billion and generates $15.68 million in revenue each year. The company earns $-87,620,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis. Forty Seven employs 57 workers across the globe. View additional information about Forty Seven.

What is Forty Seven's official website?

The official website for Forty Seven is http://www.fortyseveninc.com/.

How can I contact Forty Seven?

Forty Seven's mailing address is 1490 O`BRIEN DRIVE SUITE A, MENLO PARK CA, 94025. The company can be reached via phone at 650-352-4150 or via email at [email protected]


MarketBeat Community Rating for Forty Seven (NASDAQ FTSV)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  141 (Thanks for Voting!)
Underperform Votes:  132 (Thanks for Voting!)
Total Votes:  273
MarketBeat's community ratings are surveys of what our community members think about Forty Seven and other stocks. Vote "Outperform" if you believe FTSV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FTSV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel